Skip to main content

Table 4 Patient demographics and disease characteristics

From: Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe

 

Cohort A (n = 218)

Cohort B (n = 26)

Cohort C (n = 111)

Overall (n = 355)

Median age, years

64

61

61

63

Family history, breast/ovarian cancer, n (%)

35 (16)

3 (12)

29 (26)

67 (19)

ECOG performance status, n (%)

    

 0–1

168 (77)

26 (100)

94 (85)

288 (81)

 2–4

44 (20)

0

17 (15)

61 (17)

 Missing

6 (3)

0

0

6 (2)

AJCC stage grouping, n (%)

    

 IIIA

41 (19)

4 (15)

16 (14)

61 (17)

 IV

146 (67)

22 (85)

70 (63)

238 (67)

PgR-positive status, n (%)a

155 (71)

19 (73)

69 (62)

243 (68)

Tumor proliferation, n (%)a

    

 Ki-67 status <20 %

26 (12)

2 (8)

20 (18)

48 (14)

 Grade 3

100 (46)

11 (42)

53 (48)

164 (46)

Metastatic site, n (%)

    

 Brain

6 (3)

0

13 (12)

19 (5)

 Lung

72 (33)

6 (23)

36 (32)

114 (32)

 Liver

61 (28)

3 (12)

52 (47)

116 (33)

 Bone

118 (54)

22 (85)

60 (54)

200 (56)

  1. Abbreviations: AJCC American Joint Committee on Cancer, ECOG Eastern Cooperative Oncology Group, PgR progesterone receptor
  2. aMay reflect baseline characteristics before advanced breast cancer (ABC) diagnosis when biopsy was not conducted at ABC diagnosis